Cargando…

TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses

ABSTRACT: Cancer immunotherapy relies on improving T cell effector functions against malignancies, but despite the identification of several key transcription factors (TFs), the biological functions of these TFs are not entirely understood. We developed and utilized a novel, clinically relevant muri...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Rebecca, Mammadli, Mahinbanu, Hiner, Shannon, Suo, Liye, Yang, Qi, Sen, Jyoti Misra, Karimi, Mobin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198945/
https://www.ncbi.nlm.nih.gov/pubmed/36562825
http://dx.doi.org/10.1007/s00262-022-03323-0
_version_ 1785044830115594240
author Harris, Rebecca
Mammadli, Mahinbanu
Hiner, Shannon
Suo, Liye
Yang, Qi
Sen, Jyoti Misra
Karimi, Mobin
author_facet Harris, Rebecca
Mammadli, Mahinbanu
Hiner, Shannon
Suo, Liye
Yang, Qi
Sen, Jyoti Misra
Karimi, Mobin
author_sort Harris, Rebecca
collection PubMed
description ABSTRACT: Cancer immunotherapy relies on improving T cell effector functions against malignancies, but despite the identification of several key transcription factors (TFs), the biological functions of these TFs are not entirely understood. We developed and utilized a novel, clinically relevant murine model to dissect the functional properties of crucial T cell transcription factors during anti-tumor responses. Our data showed that the loss of TCF-1 in CD8 T cells also leads to loss of key stimulatory molecules such as CD28. Our data showed that TCF-1 suppresses surface NKG2D expression on naïve and activated CD8 T cells via key transcriptional factors Eomes and T-bet. Using both in vitro and in vivo models, we uncovered how TCF-1 regulates critical molecules responsible for peripheral CD8 T cell effector functions. Finally, our unique genetic and molecular approaches suggested that TCF-1 also differentially regulates essential kinases. These kinases, including LCK, LAT, ITK, PLC-γ1, P65, ERKI/II, and JAK/STATs, are required for peripheral CD8 T cell persistent function during alloimmunity. Overall, our molecular and bioinformatics data demonstrate the mechanism by which TCF-1 modulated several critical aspects of T cell function during CD8 T cell response to cancer. GRAPHICAL ABSTRACT: Summary Figure: TCF-1 is required for persistent function of CD8 T cells but dispensable for anti-tumor response. Here, we have utilized a novel mouse model that lacks TCF-1 specifically on CD8 T cells for an allogeneic transplant model. We uncovered a molecular mechanism of how TCF-1 regulates key signaling pathways at both transcriptomic and protein levels. These key molecules included LCK, LAT, ITK, PLC-γ1, p65, ERK I/II, and JAK/STAT signaling. Next, we showed that the lack of TCF-1 impacted phenotype, proinflammatory cytokine production, chemokine expression, and T cell activation. We provided clinical evidence for how these changes impact GVHD target organs (skin, small intestine, and liver). Finally, we provided evidence that TCF-1 regulates NKG2D expression on mouse naïve and activated CD8 T cells. We have shown that CD8 T cells from TCF-1 cKO mice mediate cytolytic functions via NKG2D. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-022-03323-0.
format Online
Article
Text
id pubmed-10198945
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-101989452023-05-21 TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses Harris, Rebecca Mammadli, Mahinbanu Hiner, Shannon Suo, Liye Yang, Qi Sen, Jyoti Misra Karimi, Mobin Cancer Immunol Immunother Research ABSTRACT: Cancer immunotherapy relies on improving T cell effector functions against malignancies, but despite the identification of several key transcription factors (TFs), the biological functions of these TFs are not entirely understood. We developed and utilized a novel, clinically relevant murine model to dissect the functional properties of crucial T cell transcription factors during anti-tumor responses. Our data showed that the loss of TCF-1 in CD8 T cells also leads to loss of key stimulatory molecules such as CD28. Our data showed that TCF-1 suppresses surface NKG2D expression on naïve and activated CD8 T cells via key transcriptional factors Eomes and T-bet. Using both in vitro and in vivo models, we uncovered how TCF-1 regulates critical molecules responsible for peripheral CD8 T cell effector functions. Finally, our unique genetic and molecular approaches suggested that TCF-1 also differentially regulates essential kinases. These kinases, including LCK, LAT, ITK, PLC-γ1, P65, ERKI/II, and JAK/STATs, are required for peripheral CD8 T cell persistent function during alloimmunity. Overall, our molecular and bioinformatics data demonstrate the mechanism by which TCF-1 modulated several critical aspects of T cell function during CD8 T cell response to cancer. GRAPHICAL ABSTRACT: Summary Figure: TCF-1 is required for persistent function of CD8 T cells but dispensable for anti-tumor response. Here, we have utilized a novel mouse model that lacks TCF-1 specifically on CD8 T cells for an allogeneic transplant model. We uncovered a molecular mechanism of how TCF-1 regulates key signaling pathways at both transcriptomic and protein levels. These key molecules included LCK, LAT, ITK, PLC-γ1, p65, ERK I/II, and JAK/STAT signaling. Next, we showed that the lack of TCF-1 impacted phenotype, proinflammatory cytokine production, chemokine expression, and T cell activation. We provided clinical evidence for how these changes impact GVHD target organs (skin, small intestine, and liver). Finally, we provided evidence that TCF-1 regulates NKG2D expression on mouse naïve and activated CD8 T cells. We have shown that CD8 T cells from TCF-1 cKO mice mediate cytolytic functions via NKG2D. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-022-03323-0. Springer Berlin Heidelberg 2022-12-23 2023 /pmc/articles/PMC10198945/ /pubmed/36562825 http://dx.doi.org/10.1007/s00262-022-03323-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Harris, Rebecca
Mammadli, Mahinbanu
Hiner, Shannon
Suo, Liye
Yang, Qi
Sen, Jyoti Misra
Karimi, Mobin
TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses
title TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses
title_full TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses
title_fullStr TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses
title_full_unstemmed TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses
title_short TCF-1 regulates NKG2D expression on CD8 T cells during anti-tumor responses
title_sort tcf-1 regulates nkg2d expression on cd8 t cells during anti-tumor responses
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198945/
https://www.ncbi.nlm.nih.gov/pubmed/36562825
http://dx.doi.org/10.1007/s00262-022-03323-0
work_keys_str_mv AT harrisrebecca tcf1regulatesnkg2dexpressiononcd8tcellsduringantitumorresponses
AT mammadlimahinbanu tcf1regulatesnkg2dexpressiononcd8tcellsduringantitumorresponses
AT hinershannon tcf1regulatesnkg2dexpressiononcd8tcellsduringantitumorresponses
AT suoliye tcf1regulatesnkg2dexpressiononcd8tcellsduringantitumorresponses
AT yangqi tcf1regulatesnkg2dexpressiononcd8tcellsduringantitumorresponses
AT senjyotimisra tcf1regulatesnkg2dexpressiononcd8tcellsduringantitumorresponses
AT karimimobin tcf1regulatesnkg2dexpressiononcd8tcellsduringantitumorresponses